Tracking linezolid levels for rifampin-resistant TB treatment
Part of Infections clinical trials.
This study checks if measuring the amount of linezolid medicine in your blood helps treat rifampin-resistant tuberculosis more safely and effectively. It is for people who have already started a treatment plan that includes linezolid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed infection with tuberculosis that is resistant to rifampin
- You have started a treatment plan that includes linezolid within the last 14 days
- You know your HIV status or are willing to be tested for HIV
- You are not pregnant at the start of the study
- You are able to follow up at Nkqubela Hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called sorfequiline, given in a combination regimen, to treat adults with drug-sensitive TB. It aims to see if sorfequiline can work as well as or better than standard treatment and shorten the time to cure.
This trial tests whether adjusting the dose of linezolid based on regular blood tests can help people with multidrug-resistant tuberculosis (MDR-TB) tolerate the medication better while on the BPaL or BPaL-M regimen. It aims to reduce side effects and improve treatment success.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Hear when a new Drug-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.